Skip to main content
. Author manuscript; available in PMC: 2014 Aug 1.
Published in final edited form as: Pharm Res. 2013 May 9;30(8):2063–2076. doi: 10.1007/s11095-013-1059-7

Table IV.

In vitro antiviral activity (EC50 and EC90), cytotoxicity (CC50) and their selectivity indices (SI) of prodrugs of ACV against HSV-1, HSV-2, HCMV and EBV.

EC50 = Compound concentration that reduces viral replication by 50%, in units of μM concentration.

EC90 = Compound concentration that reduces viral replication by 90%, in units of μM concentration.

CC50 = Compound concentration that reduces cell viability by 50%, in units of μM concentration.

SI50 = Selectivity index calculated as the CC50 divided by the EC50.

SI90 = Selectivity index calculated as the CC90 divided by the EC90.

Drug/Prodrug Herpes Simplex Virus-1 (HSV-1) Herpes Simplex Virus-2 (HSV-2) Human Cytomegalovirus (HC MV)* Epstein-Barr Virus (EBV)

EC5o (μM) EC90 (μM) CC50 (μM) SI50 (μM) SI90 (μM) EC50 (μM) EC90 (μM) CC50 (μM) SI50 (μM) SI90 (μM) EC50 (μM) EC90 (μM) CC50 (μM) SI50 (μM) SI90 (μM) EC50 (μM) EC90 (μM) CC50 (μM) SI50 (μM) SI90 (μM)

ACV/GCV* 3.43 >100 >100 >29.15 1 5.98 >100 >100 >16.72 1 0.21 0.38 >100 >476.19 >263.16 12.4 67.3 >100 >8.06 >1.49
B-ACV 181.54 >300 >300 >1.65 1 >300 >300 >300 1 1 >60 >60 234.24 <3.9 <3.9 22.3 52.8 >60 >2.69 >1.14
R-ACV 8.3 168.32 >300 >36.14 >1.78 3.4 8.89 >300 >88.24 >33.75 46.47 >300 >300 >6.46 1 10.7 49.5 >60 >5.61 >1.21
B-R-ACV 5.7 21.89 >300 >52.6 >13.7 0.27 11.39 >300 >1111.11 >26.34 70.07 99.96 >300 >4.28 >3 2.1 41.5 >60 >28.57 >1.45
12HS-ACV 1.16 6.24 296.07 255.23 47.22 0.41 >300 296.07 722.12 0.99 101.02 136.55 >300 >2.97 >2.2 35.8 55 47.3 1.32 0.86
B-12HS-ACV <0.096 0.42 >300 >3125 >714.29 <0.096 4.65 >300 >3125 >64.52 >300 >300 >300 1 1 37.2 >60 >60 >1.61 1